1627091-47-7

MLi-2 is a leucine-rich repeat kinase 2 (LRRK2) inhibitor and may be used in the treatment and prevention of Parkinson’s disease as its a precursor to the illness.

ChEBI: MLI-2 is a member of the class of indazoles that is 1H-indazole that is substituted at position 3 by a 6-(cis-2,6-dimethylmorpholin-4-yl)pyrimidin-4-yl group and at position 5 by a (1-methylcyclopropoxy)group. It is an inhibitor of leucine-rich repeat kinase 2 (LRRK2). It has a role as an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor. It is a member of indazoles, a member of pyrimidines, a member of morpholines, a member of cyclopropanes, an aromatic ether and a tertiary amino compound.

MLi-2 is an orally availableCNS activehighly potent and selective leucine-rich repe at kinase 2 (LRRK2) inhibitor. MLi-2 potently inhibits central and peripheral LRRK2 in mice.

Store at -20°C